Monday, November 05, 2007 7:05:32 AM
Monday November 5, 7:00 am ET
PRINCETON, N.J.--(BUSINESS WIRE)--Cytogen Corporation (NASDAQ: CYTO - News) today announced that it has engaged ThinkEquity Partners LLC, to assist the Company in identifying and evaluating strategic alternatives intended to enhance the future growth potential of the Company’s pipeline and maximize shareholder value. No assurances can be given that this evaluation will lead to any specific action or transaction. Cytogen does not plan to make future comments about the status of the evaluation of strategic alternatives unless there are material developments.
“We continuously evaluate our business to identify and develop prospects for maximizing value for all shareholders and look forward to working with ThinkEquity in this regard,” said Michael D. Becker, president and chief executive officer of Cytogen. “While reviewing various strategic alternatives, we will continue to advance our growth initiatives, namely building marketplace awareness for CAPHOSOL as a treatment for oral mucositis – one of the most common and debilitating side effects of a number of common cancer therapies that remains an area of serious unmet medical need.”
About ThinkEquity Partners LLC
ThinkEquity Partners LLC is a research-centric institutional investment bank focused on the growth economy. ThinkEquity Partners LLC is dedicated to providing strategic advice, in-depth research coverage and capital to corporate clients and institutional investors interested in the knowledge economy's key growth verticals: consumer business services, healthcare, media, and technology. For more information about ThinkEquity Partners LLC, please visit www.thinkequity.com. Member NASD and SIPC.
About Cytogen
Cytogen is a specialty pharmaceutical company dedicated to advancing the treatment and care of patients by building, developing, and commercializing a portfolio of oncology products. The Company's specialized sales force currently markets two therapeutic products and one diagnostic product to the U.S. oncology market. CAPHOSOL® is an advanced electrolyte solution for the treatment of oral mucositis and dry mouth that is approved in the U.S. as a prescription medical device. QUADRAMET® (samarium Sm-153 lexidronam injection) is approved for the treatment of pain in patients whose cancer has spread to the bone. PROSTASCINT® (capromab pendetide) is a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer. The Company also currently has U.S. commercial rights to SOLTAMOX™ (tamoxifen citrate), a liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. Cytogen's product-focused strategy centers on attaining sustainable growth through clinical, commercial, and strategic initiatives.
A copy of the full prescribing information for CAPHOSOL, QUADRAMET, PROSTASCINT and SOLTAMOX, including Boxed Warnings, warnings, precautions, adverse events and other safety information may be obtained in the U.S. from Cytogen Corporation by calling toll-free 800-833-3533 or by visiting the web site at http://www.cytogen.com. Cytogen’s website is not part of this press release.
http://biz.yahoo.com/bw/071105/20071105005513.html?.v=1
Recent CYTO News
- Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation • GlobeNewswire Inc. • 05/01/2024 12:47:00 PM
- Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal • GlobeNewswire Inc. • 04/24/2024 12:47:00 PM
- Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024 • GlobeNewswire Inc. • 04/04/2024 12:45:00 PM
- Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines • GlobeNewswire Inc. • 03/25/2024 12:47:00 PM
- Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal • GlobeNewswire Inc. • 02/07/2024 01:47:00 PM
- Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment • GlobeNewswire Inc. • 01/24/2024 01:47:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/22/2024 10:02:55 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/22/2024 05:15:31 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/19/2024 09:45:26 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/19/2024 09:40:50 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/19/2024 09:30:47 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 01/08/2024 10:02:56 PM
- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit • GlobeNewswire Inc. • 01/08/2024 01:47:00 PM
- Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 12/29/2023 01:47:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/11/2023 01:01:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/11/2023 01:00:31 PM
- Altamira Therapeutics Provides Investor and Business Update • GlobeNewswire Inc. • 12/11/2023 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/08/2023 02:00:02 PM
- Altamira Therapeutics to Host Investor & Business Update Call on December 11th • GlobeNewswire Inc. • 12/05/2023 05:54:05 PM
- Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement • GlobeNewswire Inc. • 11/29/2023 03:20:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/22/2023 09:30:39 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2023 01:00:23 PM
- Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business • GlobeNewswire Inc. • 11/17/2023 02:04:00 PM
- Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine • GlobeNewswire Inc. • 11/10/2023 01:47:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM